FDA Repeatedly Approved Cancer Drug Afinitor Without Proof it Extended Life

Milwaukee Journal Sentinel - Cites research conducted by Lisa Schwartz and Steven Woloshin, both professors of medicine, community and family medicine, and of The Dartmouth Institute for Health Policy and Clinical Practice, about the effects of the drug Afinitor. Despite serious side effects, the drug has been OK'd five times in the last six years, including for a common type of advanced breast cancer.